Mitochondrial Mediated Apoptosis Evaluation of Myristicin on Triple Negative Breast Cancer Model Via Bcl2/Bid Pathway
Sudhina Sufina Nazar, Aswathy Vadakkumkattle Ajaykumar, Janeesh Plakkal Ayyappan · 2026
Read Mitochondrial Mediated Apoptosis Evaluation of Myristicin on Triple Negative Breast Cancer Model Via Bcl2/Bid Pathway by Sudhina Sufina Nazar, Aswathy Vadakkumkattle Ajaykumar, Janeesh Plakkal Ayyappan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13460386.txt.
Description
Nazar, Ajaykumar, and Ayyappan test myristicin, a compound from nutmeg, against triple-negative breast cancer in this 2026 study. This cancer type lacks the hormone receptors that many drugs target, so chemotherapy remains central and new options are needed. The team treated MDA-MB-231 cancer cells in dishes, then gave the compound to mice carrying 4T1 breast tumors.
In cells, myristicin triggered mitochondria-mediated apoptosis. That is the self-destruction program run through the cell's energy centers. About 46 percent of treated cells showed death markers in flow tests. It lowered the protective protein Bcl2 while raising execution proteins such as caspase-3 and caspase-9 and the damage sensor p53. In mice, treatment shrank tumor weight and volume compared with untreated cancer controls, and tissue analyses confirmed stronger death signaling in the treated tumors.
Catalog record
| CREATOR | Sudhina Sufina Nazar, Aswathy Vadakkumkattle Ajaykumar, Janeesh Plakkal Ayyappan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |